Financial Performance - Other income decreased by approximately RMB 13.3 million or 39.3% to about RMB 20.5 million for the year ending December 31, 2025[3]. - Other losses increased by approximately RMB 57.7 million or 488.7% to about RMB 69.5 million for the year ending December 31, 2025[3]. - Loss before tax increased by approximately RMB 44.5 million or 23.9% to about RMB 230.9 million for the year ending December 31, 2025[3]. - Total loss and comprehensive expenses increased by approximately RMB 43.6 million or 23.3% to about RMB 230.9 million for the year ending December 31, 2025[4]. - The company reported a net loss of RMB 230,907,000 for the year ended December 31, 2025, compared to a net loss of RMB 186,417,000 in 2024, representing a 23.8% increase in losses year-over-year[95]. - The company reported a pre-tax loss of RMB (230,907,000) in 2025, compared to RMB (186,417,000) in 2024[191]. - The company’s total equity attributable to owners was a negative RMB 13,927,000, compared to a negative RMB 13,296,000 in 2024, indicating a deterioration in equity position[100]. - The company incurred a loss per share based on the aforementioned data, reflecting ongoing financial challenges[197]. Research and Development - R&D expenses decreased by approximately RMB 21.4 million or 13.9% to about RMB 132.8 million for the year ending December 31, 2025[3]. - The company has established a comprehensive R&D structure from early development to commercialization, enabling rapid advancement of product development[15]. - The company has multiple TCR-T cell products in preclinical research targeting conditions such as renal clear cell carcinoma and viral infections like CMV and EBV[12]. - The core product EAL® has over ten years of clinical application experience and is focused on preventing postoperative recurrence of liver cancer, with plans to commercialize in China after achieving statistically significant clinical trial results[14]. - The company is advancing clinical research on CAR-T and TCR-T cell products, including ongoing Phase I and II clinical trials to achieve data compliance for market approval[32]. - The company has established a virus vector production system that meets GMP production quality standards, enabling large-scale production of viral vectors for CAR-T cell therapy[34]. - The company has completed the enrollment of 16 subjects in the Phase I clinical trial for Dinaroside injection[9]. - The company completed the enrollment of 430 subjects in the Phase II clinical trial for EAL®[5]. Clinical Trials - CAR-T-19 injection received breakthrough therapy designation for treating patients aged 25 and under with relapsed/refractory B-ALL[8]. - The company has completed the enrollment of six subjects in the Phase I clinical trial for 6B11-OCIK injection[6]. - The company completed the enrollment of 16 subjects in the Phase I clinical trial for Dinaroside injection[9]. - The 6B11-OCIK injection for ovarian cancer has completed the enrollment of six target subjects for its Phase I clinical trial, with plans to conduct Phase II trials based on business arrangements[19]. - The CAR-T-19 injection is designed for treating B-ALL in patients aged 25 and under, with the IND application accepted in August 2019 and Phase I trials initiated in December 2020[20]. - The aT19 injection, which aims to reactivate CAR-T cells and prevent recurrence of CD19 positive tumors, has received IND approval for its Phase I clinical trial, expected to commence in February 2024[23]. Financial Position and Liquidity - Bank balances and cash are projected to increase by RMB 7.5 million from RMB 47.0 million as of December 31, 2024, to RMB 54.5 million as of December 31, 2025, primarily due to the rights issue during the reporting period[50]. - As of December 31, 2025, lease liabilities are approximately RMB 103.4 million[51]. - The company has no outstanding debts, guarantees, or other significant contingent liabilities as of December 31, 2025[52]. - The company has bank balances and cash amounting to RMB 54,458,000 and structured bank deposits of RMB 100,109,000[109]. - The company is focused on improving liquidity and cash flow through various plans and measures[109]. - The current liquidity ratios show an increase, with the current ratio rising from 0.20 in 2024 to 0.35 in 2025, and the quick ratio increasing from 0.19 to 0.34 during the same period[62]. Cost Management - Administrative expenses decreased by approximately RMB 3.5 million or 7.9% to about RMB 41.0 million for the year ending December 31, 2025[3]. - The total employee compensation for the group was approximately RMB 56.9 million for the year, a decrease from RMB 70.1 million in 2024[74]. - The company’s total costs related to clinical trial subcontracting services included in R&D expenses were RMB 19,649 thousand, down from RMB 27,299 thousand, a decrease of approximately 28.2%[1]. - The company’s financial performance indicates a focus on cost reduction strategies amid ongoing losses[198]. Shareholder and Corporate Governance - The company has not declared or proposed any dividends during the reporting period[63]. - The company will hold its annual general meeting on May 22, 2026, with a record date for eligible shareholders set for the same day[66]. - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions during the reporting period[68]. - The company has suspended share transfer registration from May 19 to May 22, 2026, to determine eligible shareholders for voting at the annual general meeting[67]. Government Support and Funding - The company is actively applying for government subsidies and believes it meets the criteria for local government support for its core R&D projects[111]. - The company has successfully obtained financial support from shareholders as needed[112]. - The company plans to invest approximately RMB 1.2 billion in the Beijing production center, with an expected annual production capacity exceeding 200,000 batches upon completion[28]. - The company raised a total of RMB 300 million from the issuance of convertible bonds, with RMB 102.3 million allocated for EAL® clinical trials and RMB 197.7 million for the construction of a new R&D and production center[56]. Employee Management - The company has implemented a performance evaluation system to determine employee salary adjustments, bonuses, or promotions, ensuring competitive compensation in the market[75]. - The company emphasizes employee training to enhance technical and product knowledge, offering tailored training programs for different positions[76]. - As of December 31, 2025, the total number of employees is 183, with 82 in production and supply chain, 50 in quality, 19 in management, and 16 in clinical support and business development[75].

Immunotech Biopharm Ltd 永泰生物製藥有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6978） 1. 目 的 1.1 委員會旨在就董事及高級管理人員薪酬的政策及結構向董事會作出 建 議、設 立 規 範 透 明 的 程 序 以 制 定 政 策、評 估 董 事 及 高 級 管 理 人 員 的 表 現、評 核 並 批 准 激 勵 計 劃（包 括 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）（經 不 時 修 訂）第 十 七 章 項 下 的 股 份 計 劃）及董事服務 合 約 的 條 款 及╱或 有 關 事 宜，及 為 所 有 董 事 及 高 級 管 理 人 員 的 薪 酬 方 案 作 出 建 議。 2. 組 成 2.1 委 員 會 由 董 事 會 不 時 委 任，其 中 大 多 數 成 員 須 為 不 時 符 合 上 市 規 則 所 訂 定 獨 立 性 規 定 的 獨 立 非 執 行 董 事。 2.2 董事會須委任委員會的一名成員（必 須 為 獨 立 非 執 行 董 事）擔任主席 （「主 席」）。 3. 會 議 永泰 ...

Immunotech Biopharm Ltd 永泰生物製藥有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6978） 5. 報告程序 – 3 – 審核委員會職權範圍 永泰生物製藥有限公司（「本公司」）根據本公司董事會（「董事會」）於2020年6月6 日通過的決議案成立審核委員會（「委員會」）。下 文 載 列 截 至2026年3月20日經修 訂的委員會的職權範圍（「職權範圍」）。職 權 範 圍 的 英 文 版 與 繁 體 中 文 版 如 有 任 何 歧 義，概 以 英 文 版 為 準。 – 1 – 1. 目 的 1.1 委 員 會 旨 在 協 助 董 事 會 建 立 正 規 且 透 明 的 安 排，以 便 董 事 會 考 慮 如 何 應 用 財 務 報 告、風 險 管 理 及 內 部 監 控 原 則，以 及 如 何 與 本 公 司 核 數 師 保 持 適 當 關 係。 2. 組 成 2.1 委員會須至少由三名成員（僅 為 非 執 行 董 事）組 成，其 中 大 多 數 必 須 為 本 公 司 獨 立 非 執 行 董 事，亦 必 須 包 括 至 少 一 名 按 香 港 聯 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 永泰生物製藥有限公司 主席兼執行董事 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6978） 董事會會議日期 永泰生物製藥有限公司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，本 公 司 計劃於2026年3月20日（星 期 五）舉 行 董 事 會 會 議，藉 以（其 中 包 括）考慮及批准本 公司及其附屬公司截至2025年12月31日 止 年 度 之 全 年 業 績 及 其 發 佈。 承董事會命 Immunotech Biopharm Ltd 永泰生物製藥有限公司 譚 錚 香 港，2026年3月10日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 譚 錚 先 生，非 執 行 董 事 楊 帆 先 生、 王 瑞 華 先 生、王 東 虎 先 生、楊 昕 先 生、劉 銳 先 生 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 永泰生物製藥有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06978 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | 本月底法定/註冊股本 ...

Group 1 - The core point of the article is that Yongtai Biological-B (06978.HK) announced an investment in a structured deposit product with SPD Bank, amounting to RMB 50 million [1] Group 2 - The investment is scheduled for February 25, 2026, indicating a long-term financial strategy [1] - The structured deposit product represents a financial instrument that may offer a fixed return, reflecting the company's approach to capital management [1]

Group 1 - The core point of the article is that Yongtai Biological-B (06978) announced an investment in a structured deposit product with a value of 50 million RMB, which will be made to Pudong Development Bank on February 25, 2026 [1] Group 2 - The investment amount is specified as 50 million RMB, indicating a significant commitment by the company [1] - The structured deposit product is a financial instrument that may offer a fixed return, reflecting the company's strategy to manage its cash reserves effectively [1] - The investment date is set for February 25, 2026, suggesting a forward-looking approach in the company's financial planning [1]

Group 1 - The core point of the article is that Yongtai Biological-B (06978) announced an investment in a structured deposit product with a value of RMB 50 million from Pudong Development Bank, scheduled for February 25, 2026 [1] Group 2 - The investment amount is specified as RMB 50 million, indicating a significant financial commitment by the company [1] - The structured deposit product is a financial instrument that may offer the company a way to manage its cash reserves while potentially earning returns [1] - The announcement reflects the company's strategy to engage in financial products that could enhance its liquidity management [1]

Group 1 - The core point of the article is that Yongtai Biological-B (06978.HK) announced an investment in a structured deposit product with SPD Bank, amounting to RMB 50 million [1] Group 2 - The investment is scheduled for February 25, 2026, indicating a future commitment by the company [1] - The structured deposit product represents a strategic financial move for the company, potentially aimed at optimizing cash management [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Immunotech Biopharm Ltd 永泰生物製藥有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6978） 須予披露交易 認購結構性存款產品 認購結構性存款產品 本公司於2026年2月25日 向 浦 發 銀 行 認 購 結 構 性 存 款 產 品，投 資 價 值 為 人 民 幣50,000,000元。 上市規則的涵義 由於結構性存款產品協議的其中一項適用百分比率（根 據 上 市 規 則 第14.07條 計 算）超 過5%，但 所 有 適 用 百 分 比 率 均 低 於25%，因 此 認 購 構 成 本 公 司 於 上 市規則第14章 下 的 一 項 須 予 披 露 交 易，須 遵 守 上 市 規 則 項 下 的 通 知 及 公 告 規 定。 訂約方資料 本 公 司 是 中 國 一 家 領 先 的 ...